Ventus Therapeutics' partner Novo Nordisk doses first participant in phase 1 clinical study for NNC6022─0001, an oral ...
Ventus Therapeutics, Inc, a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE, to develop differentiated small molecule therapeutics, announced that its partner, Novo Nordisk …